Alex’s Lemonade Stand Foundation: Bio-Therapeutics Grants

Alex’s Lemonade Stand Foundation (ALSF) is accepting applications to address the existing funding gap for investigator initiated biological clinical trials for childhood cancers. ALSF expects successfully proposals to accelerate the delivery of high impact therapeutics to children. The award aims to provide funding to support investigator-initiated clinical trials using biologic therapies, including but not limited to immunotherapy (including cell therapies), gene therapy and small molecules. Award amount varies. The application deadline is June 30, 2017 by 11:59pm ET.

The Office of Corporate and Foundation Relations has identified the following private funding opportunity:

Alex's Lemonade Stand Foundation: Bio-Therapeutics Grant
http://www.alexslemonade.org

Alex’s Lemonade Stand Foundation (ALSF) is accepting applications to address the existing funding gap for investigator initiated biological clinical trials for childhood cancers. ALSF expects successfully proposals to accelerate the delivery of high impact therapeutics to children. The award aims to provide funding to support investigator-initiated clinical trials using biologic therapies, including but not limited to immunotherapy (including cell therapies), gene therapy and small molecules. This grant category was initiated to accelerate the development of clinical trials for promising biologic approaches to treat childhood cancers. There are two tracks to this funding opportunity:

  • Track 1: Clinical trial support where all pre-clinical studies have been completed, an IND has been approved and funding is needed to conduct and complete the clinical trial. Eligible applicants must have completed pre–clinical studies in childhood cancer(s) and hold an approved IND; must have a demonstrated track record of implementing novel biologic therapies; must have experience with executing and completing clinical trials and a history of meeting projected accrual targets in a timely manner; and must have a well-defined plan and time frame to complete trial enrollment. The investigator may be working within a consortium.
  • Track 2: Pre-clinical bridge funding is available for one year to perform IND enabling studies. Subsequent funding of the trial proposed in the application will be contingent upon first obtaining all necessary regulatory approvals. Eligible applicants must have a well-defined plan to complete IND submission to be approved within one year of the start of the grant; must have experience executing and completing clinical trials that meet projected accrual targets in a timely manner; and Investigator(s) may be working within a consortium.

Indirect costs are not allowed. Awards are made to the institution, not the individual.

Application Deadline: June 30, 2017 by 11:59pm ET. Award notification made by October 2017 with project start date of February 1, 2018. Application Guidelines for the award: https://www.alexslemonade.org/sites/default/files/2017_bio_therapeutics_guidelines.pdf.

If you have any questions about this funding opportunity, please contact Kavita Hall, Associate Director of Corporate and Foundation Relations, at Kavita.hall@unc.edu or (919) 962-2013. The UNC Office of Corporate and Foundation Relations is available to provide assistance in pursuing privately funded opportunities. 

Filed under: